Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. CROI 2019, abstract 139.
Internationaal partnership zet grote stap in strijd tegen resistente tbc
jul 2021 | Bacteriële infecties, Tuberculose